Best for
All-rounder
How to buy Angiogenex shares | $0.18
Own Angiogenex shares in just a few minutes. Share price changes are updated daily.
Angiogenex Inc (AGGX) is a leading other business based in the US. It opened the day at $0.18 after a previous close of $0.18. During the day the price has varied from a low of $0.18 to a high of $0.18. The latest price was $0.18 (25 minute delay). Angiogenex is listed on the PINK. All prices are listed in US Dollars.
How to buy shares in Angiogenex
- Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: AGGX in this case.
- Research Angiogenex shares. The platform should provide the latest information available.
- Buy your Angiogenex shares. It's that simple.
Best for
Low-cost trading
Best for
US shares
Best for
Beginners
What's in this guide?
How has Coronavirus impacted Angiogenex's share price?
Since the stock market crash in March caused by coronavirus, Angiogenex's share price has had significant positive movement.
Its last market close was $0.29, which is 55.17% up on its pre-crash value of $0.13 and 187.13% up on the lowest point reached during the March crash when the shares fell as low as $0.101.
If you had bought $1,000 worth of Angiogenex shares at the start of February 2020, those shares would have been worth $1,142.86 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $2,761.90.
Angiogenex share price
Use our graph to track the performance of AGGX stocks over time.Angiogenex shares at a glance
Information last updated 2020-09-29.
| Open | $0.18 |
|---|---|
| High | $0.18 |
| Low | $0.18 |
| Close | $0.18 |
| Previous close | $0.18 |
| Change | $0 |
| Change % | 0% |
| Volume | 12,737 |
Information last updated 2020-06-04.
| 52-week range | $0.1 - $0.3 |
|---|---|
| 50-day moving average | $0.1857 |
| 200-day moving average | $0.1584 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | N/A |
Invest in Angiogenex shares with 0% commission
Other fees may apply. Your capital is at risk.
- Unlimited trades, with no dealing charges or management fees
- If your trades get copied you can earn extra money
- Create an account today in a few minutes
Share dealing platform comparison
Table: sorted by promoted deals first
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Capital is at risk.
Angiogenex price performance over time
Historical closes compared with the last close of $0.18
1 week (2020-10-15)
-37.93%
1 month (2020-09-25)
0.18
3 months (2020-07-24)
50.00%
6 months (2020-04-24)
78.22%
1 year (2019-10-24)
73.08%
Angiogenex financials
Gross profit TTM
$0
Return on assets TTM
0%
Return on equity TTM
0%
Profit margin
0%
TTM: trailing 12 months
Angiogenex share dividends
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Capital is at risk.
Angiogenex price performance over time
Historical closes compared with the last close of $0.18
| 1 week (2020-10-15) | -37.93% |
|---|---|
| 1 month (2020-09-25) | 0.18 |
| 3 months (2020-07-24) | 50.00% |
| 6 months (2020-04-24) | 78.22% |
| 1 year (2019-10-24) | 73.08% |
|---|
Angiogenex financials
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | 0% |
| Return on equity TTM | 0% |
| Profit margin | 0% |
TTM: trailing 12 months
We're not expecting Angiogenex to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Angiogenex overview
AngioGenex, Inc. (AngioGenex) is a development-stage company. The Company is a biopharmaceutical company focused on the manufacturing of products for the treatment, diagnosis and prognosis of cancer. The Company focuses to develop orally active anti-cancer drugs that act by modulating the action of the inhibitor of differentiation (Id) proteins, measurement of Id proteins in tumors and blood to create products for the diagnosis and prognosis of cancer and generating proof-of-concept data in relevant preclinical models to establish that modulation of Id genes and proteins is useful to treat non-oncologic diseases in which a surplus or deficit in the growth of blood vessels is an important part of the underlying pathology.
Frequently asked questions
More guides on Finder
-
How to buy Virpax Pharmaceuticals (VRPX) shares when it goes public
Everything we know about the Virpax Pharmaceuticals IPO, plus information on how to buy it.
-
How to buy Vivos Therapeutics (VVOS) shares when it goes public
Everything we know about the Vivos Therapeutics IPO, plus information on how to buy it.
-
How to buy Kiromic Biopharma (KRBP) shares when it goes public
Everything we know about the Kiromic Biopharma IPO, plus information on how to buy it.
-
How to buy Codiak BioSciences (CDAK) shares when it goes public
Everything we know about the Codiak BioSciences IPO, plus information on how to buy it.
-
How to buy Triller (AGGX.US) shares when it goes public
Everything we know about the Triller IPO, plus information on how to buy it.
-
How to buy Eastern Bank (EBC) shares when it goes public
Everything we know about the Eastern Bank IPO, plus information on how to buy it.
-
How to buy Wish (AGGX.US) shares when it goes public
Everything we know about the Wish IPO, plus information on how to buy it.
-
How to buy MINISO Group Holding Limited (MNSO) shares when it goes public
Everything we know about the MINISO Group Holding Limited IPO, plus information on how to buy it.
-
How to buy Playboy (PLBY) shares when it goes public
Everything we know about the Playboy IPO, plus information on how to buy it.
-
How to buy iHuman (IH) shares
Everything we know about the iHuman IPO, plus information on how to buy it.
Ask an Expert